Literature DB >> 7489358

Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy.

J Bergh1, T Norberg, S Sjögren, A Lindgren, L Holmberg.   

Abstract

The complete coding region of the p53 gene was sequenced from 316 consecutively presented breast cancers, of which 97 were lymph node positive and 206 were node negative. The p53 status was related to prognosis and effect of adjuvant therapy. In all, 69 individual mutations, 29 in node-positive tumours, were demonstrated throughout the whole coding sequence. The mutation sites were partly different for node-positive and node-negative patients. p53 mutations in the evolutionary conserved regions II and V were associated with significantly worse prognosis. Adjuvant systemic therapy, especially with tamoxifen, along with radiotherapy seemed to be of less value to p53 mutation- and lymph node-positive tumours.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7489358     DOI: 10.1038/nm1095-1029

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  80 in total

Review 1.  Soft tissue sarcomas and p53 mutations.

Authors:  H Taubert; A Meye; P Würl
Journal:  Mol Med       Date:  1998-06       Impact factor: 6.354

2.  p53-independent apoptosis induced by paclitaxel through an indirect mechanism.

Authors:  J S Lanni; S W Lowe; E J Licitra; J O Liu; T Jacks
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-02       Impact factor: 11.205

3.  Specific mutation screening of TP53 gene by low-density DNA microarray.

Authors:  Angélica Rangel-López; Alfonso Méndez-Tenorio; Kenneth L Beattie; Rogelio Maldonado; Patricia Mendoza; Guelaguetza Vázquez; Carlos Pérez-Plasencia; Martha Sánchez; Guillermo Navarro; Mauricio Salcedo
Journal:  Nanotechnol Sci Appl       Date:  2009-01-20

Review 4.  Tumor suppressor p53 and estrogen receptors in nuclear-mitochondrial communication.

Authors:  Nadi T Wickramasekera; Gokul M Das
Journal:  Mitochondrion       Date:  2013-10-29       Impact factor: 4.160

Review 5.  Molecular assessment of cancer.

Authors:  C Caldas
Journal:  BMJ       Date:  1998-05-02

6.  Establishment and characterization of a lung cancer cell line, SMC-L001, from a lung adenocarcinoma.

Authors:  So-Jung Choi; Hyeseon Lee; Chungyoul Choe; Yong-Sung Shin; Jinseon Lee; Sung-Hwan Moon; Jhingook Kim
Journal:  In Vitro Cell Dev Biol Anim       Date:  2014-02-26       Impact factor: 2.416

Review 7.  TP53 Mutations and Outcomes in Breast Cancer: Reading beyond the Headlines.

Authors:  Ashkan Shahbandi; Hoang D Nguyen; James G Jackson
Journal:  Trends Cancer       Date:  2020-02-05

8.  Rates of TP53 Mutation are Significantly Elevated in African American Patients with Gastric Cancer.

Authors:  Elke J A H van Beek; Jonathan M Hernandez; Debra A Goldman; Jeremy L Davis; Kaitlin McLaughlin; R Taylor Ripley; Teresa S Kim; Laura H Tang; Jaclyn F Hechtman; Jian Zheng; Marinela Capanu; Nikolaus Schultz; David M Hyman; Marc Ladanyi; Michael F Berger; David B Solit; Yelena Y Janjigian; Vivian E Strong
Journal:  Ann Surg Oncol       Date:  2018-05-03       Impact factor: 5.344

9.  Prognostic value of p53 and bcl-2 expression in patients treated with breast conservative therapy.

Authors:  Kyubo Kim; Eui Kyu Chie; Wonshik Han; Dong-Young Noh; In Ae Park; Do-Youn Oh; Seock-Ah Im; Tae-You Kim; Yung-Jue Bang; Sung W Ha
Journal:  J Korean Med Sci       Date:  2010-01-25       Impact factor: 2.153

10.  Classical and Novel Prognostic Markers for Breast Cancer and their Clinical Significance.

Authors:  Pankaj Taneja; Dejan Maglic; Fumitake Kai; Sinan Zhu; Robert D Kendig; Elizabeth A Fry; Kazushi Inoue
Journal:  Clin Med Insights Oncol       Date:  2010-04-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.